MDxHealth SA filings document a foreign private issuer focused on precision diagnostics for prostate cancer and other urologic diseases. The company’s Form 6-K reports furnish financial results, interim reports, press releases, governance updates and materials incorporated by reference into registration statements.
The filing record includes shareholder meeting notices, proxy and attendance materials, a share option plan, authorized-capital reports, warrant terms and acquisition-related disclosures. MDXH filings also document the completed Exosome Diagnostics acquisition through audited financial statements and pro forma financial information, along with amendments to earnout obligations related to the GPS acquisition.
MDxHealth SA expects to report preliminary, unaudited third-quarter 2026 revenue from continuing operations of approximately $22.7 million, compared with $22.7 million in the third quarter of 2025, re-presented to exclude Resolve mdx as a discontinued operation. It suspended full-year 2026 revenue guidance of $110–115 million after revenue fell short of expectations.
Tissue-based test volume was 11,232, a decrease of 11% from the prior-year period. Liquid-based test volume was 11,792, compared with 4,600; the prior-year period included Select mdx and Exo mdx from its September 2025 acquisition. Cash and cash equivalents were approximately $31.7 million as of September 30, 2026. CEO Michael K. McGarrity said the company experienced unexpected sales-force turnover following Resolve mdx’s discontinuation, which he attributed to aggressive recruiter targeting. He said the company was focused on fortifying affected territories and expected a return to growth in these end markets. The preliminary figures remain subject to quarter-end close and review procedures; actual results may differ materially.
MDxHealth SA's amended ownership disclosure reports that Bleichroeder, Bleichroeder Holdings LLC and Andrew Gundlach, identified as Chairman and CO-CEO, each beneficially own 30,571,922 ordinary shares, representing 32.04% of the outstanding shares. The reporting persons have sole voting and dispositive power over those shares.
Accounts and funds managed by Bleichroeder LP hold the shares, which were acquired on the open market and in transactions with MDxHealth at an aggregate cost of $46,267,320.19. Transactions reported for the past 60 days were all in the open market, and the per-share prices include commissions.
MDxHealth SA (MDXH) received a notice under Rule 144 that a 10% stockholder, identified as Bleichroeder, plans to sell up to 1,500,000 shares of common stock. The shares are to be sold for cash through a registered public offering, with BTIG LLC as broker and the stock listed on NASDAQ.
MDxHealth SA (MDXH) reports interim 2026 results showing revenue from continuing operations up 14% to $51.1 million, driven mainly by the ExoDx acquisition, with gross profit of $32.6 million and gross margin of 63.7%.
Higher selling, marketing, and G&A expenses, largely linked to ExoDx and new IT initiatives, lifted operating loss to $13.3 million and loss from continuing operations to $19.2 million, with total net loss at $20.4 million. The company ended June 30, 2026 with $19.2 million in cash and cash equivalents and an accumulated deficit of $423.4 million, and subsequently raised $20 million via a registered direct share placement in August 2026.
Management states that forecasts, access to additional debt or equity, and compliance with OrbiMed loan covenants support preparing accounts on a going-concern basis, but explicitly notes a material uncertainty that casts substantial doubt on the ability to continue as a going concern. MDxHealth discontinued its Resolve UTI business and closed the Plano, Texas lab, classifying these as discontinued operations with a $1.2 million loss and related impairments and exit costs. The company received Nasdaq notices for non-compliance with minimum bid price and market value rules, has regained compliance with market value, but remains out of compliance with the $1.00 minimum bid price requirement, with a remediation period through December 28, 2026.
MDxHealth SA shareholders Laurence W. Lytton and the Lytton-Kambara Foundation report beneficial ownership of 18,558,988 and 11,583,098 Ordinary Shares, respectively. These positions represent 19.5% and 12.1% of the Ordinary Shares outstanding, based on 95,417,382 shares outstanding as of August 13, 2026.
Lytton reports 3,933,448 shares with sole voting and dispositive power and 14,625,540 shares with shared voting and dispositive power. The Foundation reports 11,583,098 shares with shared voting and dispositive power and no sole voting or dispositive power. Lytton and the Foundation have agreed to a joint filing of this Schedule 13G/A.
MDxHealth SA (MDXH) reports that private investment vehicles managed by MVM Partners, LLC purchased 2,202,643 Ordinary Shares at $0.454 per share on August 13, 2026, under securities purchase agreements dated August 11, 2026. Following this transaction, these funds hold 6,903,100 Ordinary Shares. The shares are owned directly by the funds and reported as indirectly owned by MVM Partners and Eric Bednarski, who each disclaim beneficial ownership except to the extent of any pecuniary interest.
Bleichroeder LP and related parties report beneficial ownership of 31,648,563 Ordinary Shares of MDxHealth SA, representing 33.2% of the outstanding shares. These shares were accumulated for investment purposes by funds and accounts managed by Bleichroeder.
On August 11, 2026, Bleichroeder-managed funds purchased 24,229,074 Ordinary Shares from MDxHealth in a registered direct offering at $0.454 per share, subject to a 90-day lock-up on the purchased shares. Aggregate cost for the total 31,648,563 shares held is $48,420,542.58, based on open-market and issuer transactions. The stake is based on 95,417,382 shares outstanding after the offering, with Bleichroeder having sole voting and dispositive power over the reported shares.
MDxHealth SA completed a Registered Direct Offering, issuing 44,052,862 ordinary shares at $0.454 per share to several institutional investors. The transaction was conducted directly, without a placement agent, and closed on August 13, 2026, generating approximately $20.0 million in net proceeds before offering expenses.
The company plans to use these proceeds for working capital and general corporate purposes, including funding product development and expanding commercialization activities. MDxHealth amended its Articles of Association to reflect the related capital increase, bringing total outstanding ordinary shares to 95,417,382 after the offering.
MDxHealth is conducting a registered direct offering of 44,052,862 ordinary shares at $0.454 per share, expected to raise approximately $20,000,000 in gross proceeds before an estimated $200,000 of expenses. Ordinary shares outstanding will increase from 51,364,520 to 95,417,382, resulting in immediate and substantial dilution; net tangible book value per share would improve from ($2.07) to ($0.91), implying dilution of $1.36 per new share purchased. The company plans to use proceeds for general corporate and working capital purposes, including product development and commercialization expansion. As of June 30, 2026, cash and cash equivalents would rise from $19.2 million to $39.0 million on an as-adjusted basis. MDxHealth highlights risks including ongoing losses, dependence on external financing, Nasdaq notices for non-compliance with the $1.00 minimum bid price and $35 million market value of listed securities requirements, significant debt under a $100 million secured credit facility, and potential further dilution from future equity issuances.
MDxHealth reported second-quarter 2026 revenue from continuing operations of $27.2 million, up 16% from $23.4 million a year earlier, with gross profit rising to $17.9 million and gross margin of 65.7%, slightly lower than 68.6% due mainly to test mix.
Operating loss widened to $5.1 million and net loss to $9.5 million, while adjusted EBITDA fell to ($2.3) million from $1.1 million. For the first half, revenue grew 14% to $51.1 million, but operating loss more than doubled. The company discontinued its Resolve UTI business, classifying it as a discontinued operation, and placed its Delta Lab subsidiary into an Assignment for the Benefit of Creditors. Liquidity included $19.2 million of cash at June 30, 2026, and a registered direct placement of 44,052,862 shares at $0.454 per share for $20 million in gross proceeds, implying pro forma cash of $39.2 million. Total liabilities were $162.5 million against negative equity of $30.4 million.